June 2019—Positive data demonstrating the clinical value of ConfirmMDx and SelectMDx (MDxHealth, Irvine, Calif.) for prostate cancer were presented in two moderated posters at the American Urological Association annual meeting, May 1–6 in Chicago. “Clinical utility of ConfirmMDx for prostate cancer in a community urology practice” (Yonover P, et al.) and “A 2-Gene MRNA urine test for detection of high-grade prostate cancer prior to initial prostate biopsy” (Haese A, et al.) were published in the April issue, supplement 4, of the Journal of Urology.
MDxHealth, 866-259-5644